Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The significance of c-erbB-2 protein expression was immunohistochemically investigated in 32 patients with stage III breast cancer with regard to area, shape factor and DNA content of cancer cell nuclei. Thirty-one percent of the tumors showed c-erbB-2-positive cell membrane staining (10 out of 32 cases), and the cancer cells of the c-erbB-2-positive tumors had larger and more irregular nuclei with an increased DNA content. All patients with c-erbB-2 protein-positive tumors died of the disease within six years of their mastectomy. It can be concluded that positive immunohistochemical staining of c-erbB-2 protein indicates an aggressive biological behavior of the cancer cells as well as a poor prognosis in patients with stage III breast cancer.
 ...
PMID:Significance of immunohistochemically detected c-erbB-2 protein expression in stage III breast cancer, with reference to nuclear deformity, DNA content and prognosis. 168 19

Breast cancer is the second most frequent tumor in Mexico 30-50% are diagnosed in locally advanced stages requiring neoadjuvant chemotherapy. The overexpression of HER-2/neu has been identified as a chemotherapy response predictor. The objective of our study was to identify response predictive factors to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer. Data were collected from clinical records of patients with neoadjuvant anthracycline-based chemotherapy, for clinical stage III breast cancer from 1992 to 1997. Paraffin blocks were reviewed to determine histologic grade, HER-2/neu expression, and ploidy. Patients were divided in two groups: A, 56 cases responding to chemotherapy and, B, 20 nonresponders. Mean age was 50.1 and 45.4 for groups A and B, respectively (OR 7.02, p = 0.004), and those premenopausal were 43% and 70%, respectively (OR 3.1, p = 0.04). Mean tumor size was 5 cm in responders and 8 cm for nonresponders (OR 4, p = 0.02). Clinical stage III-B 16% and 70% for groups A and B (OR 12.2, p = 0.000); tumors were aneuploid in 39% of responders and 18.7% for nonresponders. HER-2 /neu was overexpressed in 64.2% and 50% for groups A and B (OR 3.6, p = 0.06). On multivariate analysis significance was conserved only for age, clinical stage, and size. HER-2/neu lost significance. Age and size were importantly related to tumor response, a higher percentage of HER-2/neu overexpression was observed in responders, without significance due to small sample size. It would be important to study a larger number of patients to obtain more conclusive results.
 ...
PMID:Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients. 1575 Jan 93